Mark A Findeis

Summary

Publications

  1. ncbi request reprint The role of amyloid beta peptide 42 in Alzheimer's disease
    Mark A Findeis
    Satori Pharmaceuticals Incorporated, 222 Berkeley Street, Suite 1040, Boston, MA 02116, USA
    Pharmacol Ther 116:266-86. 2007
  2. ncbi request reprint Peptide inhibitors of beta amyloid aggregation
    Mark A Findeis
    Praecis Pharmaceuticals Incorporated, 830 Winter Street, Waltham, MA 02451 1420, USA
    Curr Top Med Chem 2:417-23. 2002

Research Grants

Detail Information

Publications2

  1. ncbi request reprint The role of amyloid beta peptide 42 in Alzheimer's disease
    Mark A Findeis
    Satori Pharmaceuticals Incorporated, 222 Berkeley Street, Suite 1040, Boston, MA 02116, USA
    Pharmacol Ther 116:266-86. 2007
    ..Such compounds are now reaching clinical evaluation to determine how they may be of benefit in the treatment of AD...
  2. ncbi request reprint Peptide inhibitors of beta amyloid aggregation
    Mark A Findeis
    Praecis Pharmaceuticals Incorporated, 830 Winter Street, Waltham, MA 02451 1420, USA
    Curr Top Med Chem 2:417-23. 2002
    ..This article reviews efforts to adapt the structure of Abeta to the design and testing of peptide-based inhibitors of Abeta polymerization of interest as potential AD therapeutics...

Research Grants2

  1. Beta-amyloid 1-42 lowering agent for Alzheimer's Disease
    MARK FINDEIS; Fiscal Year: 2006
    ..This compound will be of interest for other neurological disorders where Ap-related toxicity may be a contributing factor. ..
  2. NC/OFQ analogs as ORL1 agonists to promote gut motility
    MARK FINDEIS; Fiscal Year: 2005
    ..Compounds will be evaluated using both in vitro and in vivo assays to select a candidate for preclinical evaluation for use as a prokinetic agent to treat postoperative ileus. ..